Wouldn't we all like to know. No news this morning.

With the volume we saw on Friday, ARWR is definitely one stock to follow on Monday.

I see opportunities here for both long term and short term.

I wouldn't be surprised if news is coming.

Yes, older folks have a hard time letting go and adapting to change. Especially in technology.

It's a good market to be in right now, voip technology.

Yes, that's what I've been saying. VPLM should give Skype a run for their money.

Hard to say. Anything is possible.

I like Calando Pharmaceuticals. Working on cancer research.

I agree. To have huge volume like that pour in the final minutes makes you wonder.

The pipeline as you say is good. Did you check out their web site? They have info on all four subsidiary companies. Each of which has projects in the works.

Pretty interesting end to the day on Friday. Volume poured in on huge buy orders.

Hard to speculate why interest in VPLM is up.

And if that's the case, VPLM could see a nice run this week.

That could be. It does seem news comes in batches for VPLM.

I agree. That cloud server news should also help give VPLM a boost.

newt, to my knowledge, VPLM provides the technology for the magic jack. They also sell it. However, they don't own it. Someone can correct me if I'm wrong.

Appreciate your insight toby. I also agree that it won't take much for VPLM to take off.

Nice day yesterday. I'm thinking today will be even better.

Obesity is a very serious problem in America. Unfortunately, pharmas and biotechs are needed to address it.

Good question. They each offer something very unique while addressing some of the nation's biggest health concerns like cancer and obesity.

When it comes to pharmas / biotechs on Nasdaq, ARWR is not only undervalued, it should be easily trading above $1.

Where's the news?

Arrowhead Research Corp. (Nasdaq: ARWR) currently has two majority-owned subsidiaries, Calando Pharmaceuticals and Ablaris Therapeutics, Inc., and has minority investments in two early-stage nanotechnology companies, Nanotope, Inc. and Leonardo Biosystems, Inc. To learn more about Arrowhead's subsidiary companies, visit http://www.arrowres.com/portfolio.html.

ARWR News posted June 21, 2011: Arrowhead Research to Present at Two Nanomedicine-Focused Events in London. Arrowhead Research Corporation (NASDAQ:ARWR - News), a nanomedicine company with development programs in oncology, obesity, and regenerative medicine, today announced that its President and Chief Executive Officer Christopher Anzalone, Ph.D., will present at two upcoming nanomedicine-focused events at the Copthorne Tara Hotel in London.

I agree. Be on the lookout for news.

After all, they need to get this thing to a buck or they are booted off Nasdaq.

Momentum is building here. I wouldn't be surprised if the company issues some news in the next week or two.

I don't see ARWR becoming delisted from Nasdaq. But that's just my opinion.

News headline from June 21: Arrowhead Research to Present at Two Nanomedicine-Focused Events in London

That's correct ricker.

Signs are pointing that way.

Perhaps others are noticing that too.

Well it is an undervalued stock in my opinion.

Last news item I can see came on June 21.

ARWR closed at .56 (up five cents) on higher volume.

Nice day yesterday.

I believe there was just a few hundred shares traded yesterday. But I could be wrong.

Stocks are up again today. Unbelievable.

The market always seems to over-react to news like that.